Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CDC25A | P30304 | 3/20 | 0.49 |
| ▸ | POLA1 | P09884 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137808 | 0.85 | NPC1L1 (0.54) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL29397341 | 0.80 | NPC1L1 (0.59) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6387174 | 0.78 | NPC1L1 (0.73) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL7124642 | 0.78 | NPC1L1 (0.73) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6391409 | 0.78 | NPC1L1 (0.73) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6390397 | 0.78 | NPC1L1 (0.73) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL29354605 | 0.78 | NPC1L1 (0.72) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL14780849 | 0.78 | CDC25A (0.71) | USP2CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL10598505 | 0.78 | CDC25A (0.71) | USP2CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL10602107 | 0.78 | CDC25A (0.71) | USP2CDC25APOLA1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719217-A1 | EVALUATION OF DELIVERY LOCATIONS FOR A VASCULAR CATHETER FOR TREATMENT OF A TARGET | Universiteit Gent (BE) | 2026-04-08 | — | — | EP | claimed |
| EP-4268231-B1 | DNA METHYLATION SEQUENCING ANALYSIS METHODS | GENECAST TAIZHOU BIOTECHNOLOGY CO LTD (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2024251719-A1 | EVALUATION OF DELIVERY LOCATIONS FOR A VASCULAR CATHETER FOR TREATMENT OF A TARGET | UNIVERSITEIT GENT (BE) | 2024-12-12 | — | — | WO | claimed |
| EP-4715948-A1 | SECONDARY BATTERY MANUFACTURING SYSTEM | LG Energy Solution, Ltd. (KR) | 2026-03-25 | — | — | EP | disclosed |
| US-20260046223-A1 | CYCLE TIME DETERMINATION IN A PROCESS CONTROL SYSTEM | ABB SCHWEIZ AG (CH) | 2026-02-12 | — | — | US | disclosed |
| EP-4586351-A2 | SECONDARY BATTERY MANUFACTURING SYSTEM AND METHOD FOR TRACKING A SECONDARY BATTERY MANUFACTURING PROCESS | LG Energy Solution, Ltd. (KR) | 2025-07-16 | — | — | EP | disclosed |
| EP-4573422-A1 | CYCLE TIME DETERMINATION IN A PROCESS CONTROL SYSTEM | ABB SCHWEIZ AG (CH) | 2025-06-25 | — | — | EP | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| CN-119678112-A | Cycle time determination in a process control system | ABB瑞士股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-222461633-U | Battery performance and life-span detection device | 苏州麦稻能源科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118244143-A | Battery capacity performance tester and testing method | 苏州麦稻能源科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024037706-A1 | CYCLE TIME DETERMINATION IN A PROCESS CONTROL SYSTEM | ABB SCHWEIZ AG (CH) | 2024-02-22 | — | — | WO | disclosed |
| CN-117134667-A | Full-speed-domain position-free sensor control method for permanent magnet linear motor | 山东天海能源科技发展有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4268231-A1 | DNA METHYLATION SEQUENCING ANALYSIS METHODS | Genecast Biotechnology Co., Ltd (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023278109-A1 | DEUTERATED ORGANOTIN COMPOUNDS, METHODS OF SYNTHESIS AND RADIATION PATTERNING | INPRIA CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022156089-A1 | DNA METHYLATION SEQUENCING ANALYSIS METHODS | GENECAST BIOTECHNOLOGY CO., LTD (CN) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | NPC1L1 4113/4885USP2 1739/4885LMNA 1387/4885 |
| US-20260046223-A1 | CYCLE TIME DETERMINATION IN A PROCESS CONTROL SYSTEM | RAD1, CCNC, CCNO | NPC1L1 4109/4885USP2 697/4885LMNA 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.